Skip to main content

Table 1 Patient and treatment characteristics

From: Pelvic Ewing sarcoma: a retrospective outcome analysis of 104 patients who underwent pelvic tumor resection at a single supra-regional center

  All patients Primary Bone metastasis Multifocal Locally recurrent Extraskeletal LTFU
n % n % n % n % n % n % n %
  104 100 84 80.7 51 4.8 62 5.8 22 1.9 2 1.9 71 6.7
Sex
 Male 59 56.7 50 59.5 3 60 3 50 0   1 50 2 28.6
 Female 45 43.2 34 40.5 21 40 32 50 22 100 1 50 51 71.4
Age (years)        
 Mean 18.1 17.5 17.8 29 19 18.5 15.7
 Range 2–53 2–53 12–26 12–45 12–24 15–22 9–26
Tumor size
 Mean (cm) 8.8       
 < 9 cm 51 49 38 45.2 41 80 22 33.3 22 100 2 100 51 71.4
> 9 cm 43 41.3 38 45.2 1 20 3 50 0   0   1 14.3
 Unknown 10 9.6 8 9.5 0   1 16.6 0   0   1 14.3
Tumor volume               
 < 200 ml 18 17.3             
 > 200 ml 35 33.6             
 Unknown 51 49             
Tumor location        
 Upper posterior 52 50 43 51.2 51 100 2 33.3 0   0   31 42.9
 Lower anterior 31 29.8 25 29.8 0   22 33.3 12 50 0   4 57.1
 Periacetabular 18 17.3 15 17.8 0   2 33.3 1 50 0   0  
 Gluteal 2 1.9 0   0   0   0   2 100 0  
 Unknown 1 0.9 1 1.2 0   0   0   0   0  
Surgical procedure
 Internal intraarticular 51 49 43 51.2 0   22 33.3 12 50 1 50 5 71.4
 Internal extraarticular 13 12.5 9 10.7 0   2 33.3 1 50 1 50 0  
 Internal (without joint involvement) 39 37.5 31 36.9 51 100 2 33.3 0   0   21 28.6
 Hindquarter amputation 1 0.9 1 1.2 0   0   0   0   0  
Resection type (Enneking)        
 P1a 3 2.9 0   31 60 0   0   0   11 14.3
 P1b 1 0.9 0   1 20 0   0   0   0  
 P1-2 2 1.9 2 2.4 0   0   0   0   0  
 P1c 31 29.8 27 32.1 1 20 2 33.3 0   0   1 14.3
 P1c + HS 2 1.9 2 2.4 0   0   0   0   0  
 P1-2-3 2 1.9 2 2.4 0   0   0   0   0  
 P1-2-4 14 13.5 11 13.1 0   0   0   2 100 1 14.3
 P1-2-4 + HS 2 1.9 2 2.4 0   0   0   0   0  
 P1-2-3-4 15 14.4 12 14.3 0   2 33.3 1 50 0   0  
 P1-2-3-4 + HS 1 0.9 1 1.2 0   0   0   0   0  
 P2 1 0.9 0   0   0   0   0   1 14.3
 P2-3 14 13.5 12 14.3 0   12 16.6 12 50 0   1 14.3
 P3 15 14.4 12 14.3 0   1 16.6 0   0   2 28.6
 Unknown 1 0.9 1 1.2 0   0   0   0   0  
Reconstruction types        
 Hip transposition 33 31.7             
 Hip transposition w/proximal femur replacement 9 8.7             
 Hip transposition spacer 2 1.9             
 Pelvic implant 1 0.9 Combined with hip transposition, n = 1
 Flail hip 1 0.9 Combined with hip transposition, n = 1
 Screw-rod reconstruction w/bone cement sheath 19 18.3             
 Autologous iliac bone graft osteosynthesis 6 5.8 Combined with hip transposition, n = 1
 Autologous fibula bone graft osteosynthesis 5 4.8 Combined with hip transposition, n = 1
 Allograft osteosynthesis 7 6.7             
 Soft tissue reconstruction only 21 20.2             
EWSR 1 translocation status
 Present 62 59.6       
 Absent 2 1.9       
 Unknown 40 38.5       
Histologic response to neoadjuvant chemotherapy (Salzer-Kuntschik)        
 1 (no vital tumor) 54 51.9 46 54.8 51 100 1 16.6 0   0   31 42.9
 2 (isolated cells) 6 5.8 3 3.6 0   1 16.6 0   0   2 28.6
 3 (< 10% viable cells) 22 21.2 18 21.4 0   0   0   2 100 2 28.6
 4 (10–50% viable cells) 13 12.5 11 13.1 0   22 33.3 12 50 0   0  
 5 (> 50% viable cells) 5 4.8 3 3.6 0   2 33.3 0   0   0  
 6 (no response to chemo) 1 0.9 0   0   0   1 50 0   0  
 Unknown 3 2.9 3 3.6 0   0   0   0   0  
Surgical margins               
 R0 98 94.2 78 92.8 51 100 62 100 22 100 2 100 71 100
 Planned R1 2 1.9 2 2.4 0   0   0   0   0  
 Unplanned R1 2 1.9 2 2.4 0   0   0   0   0  
 Unknown 2 1.9 2 2.4 0   0   0   0   0  
Disease extent
 Localized 34 32.7 34 40.5 0   0   0   0   0  
 Metastatic at diagnosis 45 43.3 30 35.7 51,3 100 62 100 22 100 2 100 21 28.6
 Metastatic after pelvic resection 17 16.3 17 20.2 0   0   0   0   0  
 Unknown 8 7.7 3 3.6 0   0   0   0   5 71.4
Number of metastatic organ sites        
 Single (one other organ system)    22            
 Multiple (> 1 other organ systems)    7            
Local recurrence               
  8 7.7 6 7.1 0   2 33.3 0   0   0  
Radiation
 Yes 81 77.8             
 Neoadjuvant 17 16.3 14 16.6 0   22,4 33.3 22 100 0   0  
 Adjuvant 53 51 46 54.8 3 60 1 16.6 0   1 50 2 28.6
 Other 11 10.6 9 10.7 0   0   0   1 50 1 14.3
 No 17 16.3 12 14.3 21 40 3 50 0   0   11 14.3
 Unknown 6 5.8 3 3.6 0   0   0   0   3 42.9
  1. 1One patient with pelvic bone metastasis was also lost to follow-up
  2. 2One patient with locally recurrent ES after definite radiation and initially multifocal ES
  3. 3One patient presented with a metachronic solitary bone metastasis, received pelvic resection, and developed other distant metastases later on; four other patients presented with synchronous solitary pelvic bone metastasis
  4. 4Both locally recurrent patients received prior definite radiation
\